Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2018 Publisher: Correvio, 15 Rue du Bicentenaire, 92800 Puteaux, France, Phone number: +44 (0)203 002 8114, Email: medinfo@cardiome.com
Zevtera 500 mg powder for concentrate for solution for infusion.
| Pharmaceutical Form |
|---|
|
Powder for concentrate for solution for infusion. White, yellowish to slightly brownish, cake to broken cake or powder. The pH of the reconstituted solution is between 4.5 and 5.5. |
Each vial contains 500 mg of ceftobiprole (as 666.6 mg ceftobiprole medocaril sodium). After reconstitution, each mL of concentrate contains 50 mg ceftobiprole (as 66.7 mg of ceftobiprole medocaril sodium).
Excipient (s) with known effect: Each vial contains approximately 1.3 mmol (29 mg) sodium.
For a full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Ceftobiprole medocaril |
Ceftobiprole exerts bactericidal activity through binding to important penicillin-binding proteins (PBPs) in susceptible species. |
| List of Excipients |
|---|
|
Citric acid monohydrate |
20 mL clear type I glass vials fitted with a grey bromobutyl elastomeric closure and an aluminium seal with a blue plastic flip-off cap.
Pack size: 10 vials.
Correvio, 15 Rue du Bicentenaire, 92800 Puteaux, France, Phone number: +44 (0)203 002 8114, Email: medinfo@cardiome.com
PL 48998/0001
20/11/2013
| Drug | Countries | |
|---|---|---|
| ZEVTERA | Austria, Canada, Ecuador, Spain, Finland, Poland, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
